Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Gain Therapeutics, Inc. (GANX) had Free Cash Flow per Share of $-0.56 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-20.16M |
|
-- |
|
-- |
|
$18.71M |
|
$-18.71M |
|
$-0.59M |
|
$-19.30M |
|
$-19.30M |
|
$-20.16M |
|
$-20.16M |
|
$-20.16M |
|
$-20.16M |
|
$-18.71M |
|
$-18.62M |
|
32.97M |
|
32.97M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$22.24M |
|
$0.07M |
|
$0.58M |
|
$22.82M |
|
$3.35M |
|
$0.30M |
|
$0.90M |
|
$4.25M |
|
$18.56M |
|
$18.56M |
|
$18.56M |
|
42.07M |
|
| Cash Flow Statement Financials | |
$-18.47M |
|
-- |
|
$28.45M |
|
$10.42M |
|
$20.87M |
|
$10.46M |
|
$1.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.63 |
|
-- |
|
-- |
|
0.02 |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-108.60% |
|
-108.60% |
|
-88.35% |
|
-106.87% |
|
$0.44 |
|
|
Free Cash Flow per Share |
$-0.56 |
$-0.56 |
|